South Korean company Dong-A ST wins FDA approval for Stelara biosimilar
South Korea-based Dong-A ST has received a US Food and Drug Administration (FDA) approval for Imuldosa (ustekinumab-srlf/DMB-3115), a biosimilar that …
Post
-
-
FDA AdCom votes in favour of Stealth’s Barth syndrome drug
A US Food and Drug Administration (FDA) advisory committee (AdCom) has voted in support of Stealth Biotherapeutics’ first-line Barth syndrome …
-
Global awareness and geographic variations of plaque psoriasis
Psoriasis is an autoimmune skin condition that causes a rash with itchiness and discomfort. The most common type of psoriasis is …
-
Roche wins first-line approval for PI3K inhibitor combo in breast cancer
The US Food and Drug Administration (FDA) has approved Roche’s Itovebi (inavolisib) in combination with Pfizer’s Ibrance (palbociclib) and AstraZeneca’s …
-
XtalPi’s AI biologics discovery platform licensed to Janssen Biotech
XtalPi, an AI drug discovery company and subsidiary of Ailux Biologics, has entered a licensing agreement with Janssen Biotech, a …
-
Activist investor Starboard cries foul play in exec U-turn at Pfizer
Starboard Value, which recently took a $1bn stake in Pfizer, has claimed “coercive conduct” following a U-turn from two former …
-
Booster Therapeutics to develop proteasome activator medicines
Booster Therapeutics has announced its inception, backed by a $15m investment, to develop a new class of proteasome activator medicines …
-
KeyBioscience and Eli Lilly extend partnership for obesity treatments
Nordic Bioscience subsidiary KeyBioscience has announced an extension of its strategic partnership with Eli Lilly, focusing on the development of …
-
CPHI Europe: Targeting supply chain bottlenecks key for cell and gene therapies
Cell therapies stand at the frontier of medicine and hold the potential to potentially cure diseases, said Angela Vollstedt, global …
-
CPHI Europe: Overcoming the unique challenges with high-concentration mAbs
There is an increasing number of high-concentration mAbs among approved therapeutics, with 76% of US Food and Drug Administration (FDA)-approved mAbs …
-
Bluebird bio’s Skysona led to seven cases of blood cancer in gene therapy trials
The side effects of bluebird bio’s gene therapy Skysona (elivaldogene autotemcel) have been thrust back into the spotlight after new …
-
Paediatric type 2 diabetes faces significant underdiagnosis in China
In China, type 2 diabetes has become an increasingly prevalent, serious public health challenge. But despite the growing challenge, relatively …
-
Biogen scores breakthrough status for anti-rejection transplant medication
The US Food and Drug Administration (FDA) has granted a breakthrough therapy designation for its monoclonal antibody felzartamab as a …
-
Lilly and insitro team up to develop AI-powered siRNA metabolic drugs
Eli Lilly has teamed up with insitro to develop treatments for metabolic diseases, combining insitro’s artificial intelligence (AI) machine learning …
-
England witnesses sharp rise in food allergy incidence
According to the most recent European Health Interview Survey for 2019 to 2020, allergy is the most common chronic health …
